Summary:
- Structure Therapeutics' stock sees a surge following Eli Lilly's positive Phase 3 diabetes drug data.
- Wall Street analysts see a significant upside for Structure Therapeutics' share price.
- Mid-stage trial results for Structure's aleniglipron, targeting obesity and diabetes, are anticipated by late 2025.
Structure Therapeutics (GPCR, Financial) witnessed a remarkable upswing in its stock price, spurred by Eli Lilly's promising Phase 3 results for their oral diabetes drug, orforglipron. Structure Therapeutics is currently advancing its own oral GLP-1 agonist, aleniglipron, through mid-stage trials aimed at obesity and diabetes, with results expected by late 2025.
Wall Street Analysts' Insights
According to forecasts from 12 analysts, Structure Therapeutics Inc (GPCR, Financial) is projected to reach an average price target of $81.42 over the next year. These projections range from a high estimate of $118.00 to a low of $50.00, suggesting a remarkable potential upside of 279.65% from the current trading price of $21.45. For more comprehensive estimate data, visit the Structure Therapeutics Inc (GPCR) Forecast page.
The consensus from 13 brokerage firms rates Structure Therapeutics Inc (GPCR, Financial) with an average recommendation of 1.6, indicating an "Outperform" rating. The scale used ranges from 1, representing a Strong Buy, to 5, indicating a Sell recommendation.
